share_log

SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Gene Salkind(53.1%)

SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Gene Salkind(53.1%)

SC 13D/A：超過5%持股股東披露文件(修正)-Gene Salkind(53.1%)
美股SEC公告 ·  08/23 04:05

牛牛AI助理已提取核心訊息

On August 6, 2024, Dr. Gene Salkind, a practicing neurosurgeon and Chairman of the Board of Mobiquity Technologies, Inc., filed an amendment to the Schedule 13D, disclosing a significant ownership stake in the company. The filing, which is an update to a previous Schedule 13D filing, indicates that Dr. Salkind, along with his wife and a family trust, beneficially owns 8,805,239 common shares of Mobiquity Technologies, representing approximately 53.1% of the company's outstanding common shares. This ownership includes convertible notes, options, and warrants for additional shares. The filing also notes that Dr. Salkind has no current plans that would result in any major changes to the company's structure or operations as outlined in the Schedule 13D instructions. The acquisition of shares by Dr. Salkind and his associated parties was funded through personal funds over several years. Notably, the reporting person received 7,675,160 common shares upon the automatic conversion of Series H Preferred Stock after the company's stock traded above $2 per share between July 24, 2024, and August 6, 2024. This conversion also included additional shares for accrued and unpaid dividends.
On August 6, 2024, Dr. Gene Salkind, a practicing neurosurgeon and Chairman of the Board of Mobiquity Technologies, Inc., filed an amendment to the Schedule 13D, disclosing a significant ownership stake in the company. The filing, which is an update to a previous Schedule 13D filing, indicates that Dr. Salkind, along with his wife and a family trust, beneficially owns 8,805,239 common shares of Mobiquity Technologies, representing approximately 53.1% of the company's outstanding common shares. This ownership includes convertible notes, options, and warrants for additional shares. The filing also notes that Dr. Salkind has no current plans that would result in any major changes to the company's structure or operations as outlined in the Schedule 13D instructions. The acquisition of shares by Dr. Salkind and his associated parties was funded through personal funds over several years. Notably, the reporting person received 7,675,160 common shares upon the automatic conversion of Series H Preferred Stock after the company's stock traded above $2 per share between July 24, 2024, and August 6, 2024. This conversion also included additional shares for accrued and unpaid dividends.
2024年8月6日，Mobiquity Technologies公司董事會主席、神經外科醫生Gene Salkind博士遞交了一份修訂後的13D表格，披露他在該公司擁有大量股權。該表格是對之前的13D表格的更新，顯示出Gene Salkind博士及其妻子和家族信託有益擁有Mobiquity Technologies公司的8,805,239股普通股，約佔公司流通普通股的53.1%。這份持股包括可轉債、期權和warrants。文件還指出，Gene Salkind博士目前沒有任何計劃會導致公司的結構或業務發生重大變化，這一點在13D表格的說明中有提及。Gene Salkind博士及其相關方的股份購買是通過個人資金在幾年時間內進行的。值得注意的是，報告人在2024年7月24日至8月6日期間，當該公司股票交易價格超過每股2美元時，自動將H系列優先股轉換成了767,5160股普通股。這次轉換還包括了因爲應計未付股息而獲得的額外股份。
2024年8月6日，Mobiquity Technologies公司董事會主席、神經外科醫生Gene Salkind博士遞交了一份修訂後的13D表格，披露他在該公司擁有大量股權。該表格是對之前的13D表格的更新，顯示出Gene Salkind博士及其妻子和家族信託有益擁有Mobiquity Technologies公司的8,805,239股普通股，約佔公司流通普通股的53.1%。這份持股包括可轉債、期權和warrants。文件還指出，Gene Salkind博士目前沒有任何計劃會導致公司的結構或業務發生重大變化，這一點在13D表格的說明中有提及。Gene Salkind博士及其相關方的股份購買是通過個人資金在幾年時間內進行的。值得注意的是，報告人在2024年7月24日至8月6日期間，當該公司股票交易價格超過每股2美元時，自動將H系列優先股轉換成了767,5160股普通股。這次轉換還包括了因爲應計未付股息而獲得的額外股份。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間